Novacyt Sa Stock Today
| NVYTF Stock | USD 0.64 0.06 8.57% |
Performance0 of 100
| Odds Of DistressLess than 23
|
Novacyt SA is trading at 0.64 as of the 20th of December 2024. This is a 8.57% down since the beginning of the trading day. The stock's lowest day price was 0.64. Novacyt SA has about a 23 % chance of experiencing some form of financial distress in the next two years of operation but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 21st of October 2024 and ending today, the 20th of December 2024. Click here to learn more.
Novacyt S.A., together with its subsidiaries, engages in the development, manufacture, contract design, and commercialization of diagnostic products for cancer and infectious diseases in the United Kingdom, rest of Europe, the United States, the Asia Pacific, the Middle East, and Africa. The company has 70.63 M outstanding shares. More on Novacyt SA
Moving against Novacyt Pink Sheet
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Novacyt Pink Sheet Highlights
| Business Concentration | Medical Devices, Healthcare (View all Sectors) |
Novacyt SA [NVYTF] is a Pink Sheet which is traded between brokers as part of OTC trading. The company currently falls under 'Micro-Cap' category with a current market capitalization of 83.34 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Novacyt SA's market, we take the total number of its shares issued and multiply it by Novacyt SA's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Novacyt SA classifies itself under Healthcare sector and is part of Medical Devices industry. The entity has 70.63 M outstanding shares.
Novacyt SA has accumulated about 99.65 M in cash with 15.69 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.41, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Novacyt SA Probability Of Bankruptcy
Ownership AllocationNovacyt SA maintains a total of 70.63 Million outstanding shares. Novacyt SA secures 3.49 % of its outstanding shares held by insiders and 1.6 % owned by institutional investors. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Novacyt Ownership Details
Novacyt SA Risk Profiles
| Mean Deviation | 1.63 | |||
| Standard Deviation | 4.56 | |||
| Variance | 20.75 | |||
| Risk Adjusted Performance | (0.08) |
Novacyt Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Novacyt SA without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Equity Search Now
Equity SearchSearch for actively traded equities including funds and ETFs from over 30 global markets |
| All Next | Launch Module |
Novacyt SA Corporate Management
| Steve Gibson | Group Controller | Profile | |
| David Franks | Chief Officer | Profile | |
| Grald Ulrich | Chief Devel | Profile | |
| James McCarthy | Acting CFO | Profile | |
| Bryan Close | Chief Officer | Profile | |
| Wendy Karban | Group Mang | Profile | |
| Paul Oladimeji | Group RD | Profile |
Other Information on Investing in Novacyt Pink Sheet
Novacyt SA financial ratios help investors to determine whether Novacyt Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Novacyt with respect to the benefits of owning Novacyt SA security.